224 related articles for article (PubMed ID: 14574458)
1. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
Hungria VT; Latrilha MC; Rodrigues DG; Bydlowski SP; Chiattone CS; Maranhão RC
Cancer Chemother Pharmacol; 2004 Jan; 53(1):51-60. PubMed ID: 14574458
[TBL] [Abstract][Full Text] [Related]
2. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE.
Pinheiro KV; Hungria VT; Ficker ES; Valduga CJ; Mesquita CH; Maranhão RC
Cancer Chemother Pharmacol; 2006 May; 57(5):624-30. PubMed ID: 16133527
[TBL] [Abstract][Full Text] [Related]
3. Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE).
Teixeira RS; Curi R; Maranhão RC
J Pharm Pharmacol; 2004 Jul; 56(7):909-14. PubMed ID: 15233870
[TBL] [Abstract][Full Text] [Related]
4. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients.
Maranhão RC; Graziani SR; Yamaguchi N; Melo RF; Latrilha MC; Rodrigues DG; Couto RD; Schreier S; Buzaid AC
Cancer Chemother Pharmacol; 2002 Jun; 49(6):487-98. PubMed ID: 12107554
[TBL] [Abstract][Full Text] [Related]
5. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma.
Azevedo CH; Carvalho JP; Valduga CJ; Maranhão RC
Gynecol Oncol; 2005 Apr; 97(1):178-82. PubMed ID: 15790455
[TBL] [Abstract][Full Text] [Related]
6. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies.
Rodrigues DG; Maria DA; Fernandes DC; Valduga CJ; Couto RD; Ibañez OC; Maranhão RC
Cancer Chemother Pharmacol; 2005 Jun; 55(6):565-76. PubMed ID: 15726368
[TBL] [Abstract][Full Text] [Related]
7. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide.
Valduga CJ; Fernandes DC; Lo Prete AC; Azevedo CH; Rodrigues DG; Maranhão RC
J Pharm Pharmacol; 2003 Dec; 55(12):1615-22. PubMed ID: 14738586
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles.
Daminelli EN; Martinelli AE; Bulgarelli A; Freitas FR; Maranhão RC
Cardiovasc Drugs Ther; 2016 Oct; 30(5):433-443. PubMed ID: 27628679
[TBL] [Abstract][Full Text] [Related]
10. Plasma kinetics of a cholesterol-rich microemulsion in subjects with heterozygous beta-thalassemia.
Naoum FA; Gualandro SF; Latrilha Mda C; Maranhão RC
Am J Hematol; 2004 Dec; 77(4):340-5. PubMed ID: 15551284
[TBL] [Abstract][Full Text] [Related]
11. Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nano-emulsion.
Lo Prete AC; Maria DA; Rodrigues DG; Valduga CJ; Ibañez OC; Maranhão RC
J Pharm Pharmacol; 2006 Jun; 58(6):801-8. PubMed ID: 16734981
[TBL] [Abstract][Full Text] [Related]
12. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
13. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
Pires LA; Hegg R; Valduga CJ; Graziani SR; Rodrigues DG; Maranhão RC
Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
[TBL] [Abstract][Full Text] [Related]
14. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors.
Teixeira RS; Valduga CJ; Benvenutti LA; Schreier S; Maranhão RC
J Pharm Pharmacol; 2008 Oct; 60(10):1287-95. PubMed ID: 18812021
[TBL] [Abstract][Full Text] [Related]
15. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia.
Maranhão RC; Garicochea B; Silva EL; Dorlhiac-Llacer P; Cadena SM; Coelho IJ; Meneghetti JC; Pileggi FJ; Chamone DA
Cancer Res; 1994 Sep; 54(17):4660-6. PubMed ID: 8062260
[TBL] [Abstract][Full Text] [Related]
16. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
17. Effects in post-menopausal women of transdermal estrogen associated with progestin upon the removal from the plasma of a microemulsion that resembles low-density lipoprotein (LDL).
Melo NR; Latrilha MC; Santos RD; Pompei LM; Maranhão RC
Maturitas; 2005 Apr; 50(4):275-81. PubMed ID: 15780526
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
20. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
